Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley

Valeant Pharma (NYSE: VRX) August and September call option implied volatility of 62 compares to its 52-week range of 33 to 173 into Morgan Stanley’s upgrade to Overweight and raising its price target to $42 from $33.

You May Also Be Interested In

• Market Vectors Gold Miners ETF (GDX) call put ratio 3.1 calls to 1 put with a focus on August 7 weekly calls as share price up 4.1%
• AST SpaceMobile (ASTS) call put ratio 4.2 calls to 1 put with a focus on August 7 weekly 70 calls into quarter results
• Firefly Aerospace (FLY) call put ratio 12.9 calls to 1 put into quarter results